• Home
  • Breaking News
  • Privacy Policy
  • Email Whitelisting
No Result
View All Result
Money Profit News
No Result
View All Result
Home Breaking News

‘End of the war is in sight’ — Cramer says Dr. Gottlieb’s end-of-pandemic call bigger than jobs data

by
November 5, 2021
in Breaking News
0
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

Related Posts

IMF says risks to financial stability have increased, calls for vigilance

Awaiting possible indictment, Trump rallies in Waco and vows to ‘destroy the deep state’

Mississippi tornadoes kill 23, injure dozens overnight

Biden declares emergency as crews dig through storm wreckage

CNBC’s Jim Cramer on Friday took comfort in a prediction by Dr. Scott Gottlieb that the pandemic phase of Covid could be over by January.

“Dr. Gottlieb basically said the war’s over, and that’s just incredible,” Cramer said. Gottlieb, who had served as FDA chief under former President Donald Trump, is currently a Pfizer board member.

“By Jan. 4, this pandemic may well be over, at least as it relates to the United States, after we get through this delta wave of infection,” Gottlieb said on “Squawk Box.” “We’ll be in a more endemic phase” after that.

Gottlieb referenced Jan. 4 because that’s the new deadline for the Biden administration’s mandate for larger U.S. companies to ensure their employees are fully vaccinated or regularly tested for Covid.

“The end of the war is in sight,” Cramer said.

Gottlieb’s comments made on CNBC earlier Friday morning were more important than the strong October jobs numbers, the “Mad Money” host said.

“They were talking about employment, I don’t even care about the employment numbers — the pandemic ended,” Cramer said. “It sounds like it’s over.”

“Today is a good day,” Cramer said, referring to Pfizer’s announcement that internal data showed its oral Covid pill — when administered with a widely used HIV drug — indicated an 89% reduction in the risk of hospitalization or death in adults who’ve been exposed to the coronavirus. Pfizer shares were up more than 8% on Friday morning.

“The only people who are unhappy are the people who own the stocks that required you to stay inside,” Cramer said. So-called economic reopening stocks advanced Friday morning while stay-at-home names came under pressure.

Merck‘s antiviral Covid pill, developed with Ridgeback Biotherapeutics, was shown to reduce the risk of hospitalization and death from Covid by 50%, according to internal data released early last month. Merck shares were down nearly 9% on Friday, with the company facing competition in treatments.

Unlike Pfizer, Merck does not have a Covid vaccine.

Disclosure: Scott Gottlieb is a CNBC contributor and is a member of the boards of Pfizer, genetic testing start-up Tempus, health-care tech company Aetion and biotech company Illumina. He also serves as co-chair of Norwegian Cruise Line Holdings? and Royal Caribbean’s “Healthy Sail Panel.”

Next Post

1st Look at Local Housing Markets in October

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

email

Get the daily email about stock.

Please Enter Your Email Address:

By opting in you agree to our Privacy Policy. You also agree to receive emails from us and our affiliates. Remember that you can opt-out any time, we hate spam too!

Popular Posts

Breaking News

Mississippi tornadoes kill 23, injure dozens overnight

by
March 26, 2023
0

Debris covers a damaged structure in Rolling Fork, Miss,. on Saturday, March 25, 2023. Powerful tornadoes tore through the Deep...

Read more

Mississippi tornadoes kill 23, injure dozens overnight

Awaiting possible indictment, Trump rallies in Waco and vows to ‘destroy the deep state’

IMF says risks to financial stability have increased, calls for vigilance

Biden declares emergency as crews dig through storm wreckage

Top 5 China Stocks To Buy And Watch: 3 Internet Giants Are Actionable

The Stock Market Hopes the Worst Is Over. Experience Says It’s Not.

Load More

All rights reserved by www.moneyprofitnews.com

  • Home
  • Breaking News
  • Privacy Policy
  • Email Whitelisting
No Result
View All Result
  • Email Whitelisting
  • Home
  • Privacy Policy

moneyprofitnews